<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018235</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC QLQ BR45</org_study_id>
    <nct_id>NCT04018235</nct_id>
  </id_info>
  <brief_title>Psychometric Properties of the Updated Module on Assessing Quality of Life of Patients With Breast Cancer</brief_title>
  <acronym>EORTCQLQBR45</acronym>
  <official_title>An International Phase 4 Field Study to Analyse the Psychometric Properties of the Updated Module on Assessing Quality of Life of Patients With Breast Cancer (EORTC QLQ-BR23 Update- EORTCQLQ BR45)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helios University Hospital Wuppertal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Câncer de Barretos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Rijeka</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Evangelische Kliniken Gelsenkirchen, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nazionale Tumori Fondazione Pascale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Oncologico Veneto IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncology Department Hospital of Navarre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tumor- und Brust­zentrum ZeTuP St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Global Health and Medicine, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King Hussein Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helios University Hospital Wuppertal</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Females breast cancer is still the most frequent type of cancer in Europe with 21 per 100,000
      women .The EORTC QLQ-BR23 was one of the first modules developed to be used in conjunction
      with the core questionnaire EORTC QLQ-C30 and was published in 1996. Since the beginning of
      the work on the EORTC QLQ-BR23 some 20 years ago, much knowledge has been gathered about the
      epidemiology of breast cancer, and major advances have been made with regard to diagnostic
      and therapeutic options. Therefore, the EORTC QLG decided to update the BC23. A phase 1 to 3
      module development project has been completed. This resulted in a 45 item module, retaining
      23 of the original items and adding 22 new items, particularly tapping into the side effects
      of new systemic and local therapies.

      The aim of the Phase 4 study is to test the scale structure, reliability, responsiveness to
      change, and validity of the EORTC QLQ-BC45 in conjunction with the EORTC QLQ- C30 in patients
      diagnosed with breast cancer. Participants will be enrolled in three groups according to
      their disease stage (1. localized disease or locally advanced disease, 2. metastatic disease,
      3. follow up). Various combinations of therapies are permissible, resulting in a total of 17
      subgroups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psychometric Properties of the EORTC QLQ-BR45</measure>
    <time_frame>baseline and for some patients 1-2 weeks later (test-retest) or 3 month later (responsiveness-to-change)</time_frame>
    <description>Psychometric Properties of the EORTC QLQ-BR45 (scale structure, reliability, internal consistency, responsiveness to change, and validity of the EORTC QLQ-BC45 in conjunction with the EORTC QLQ- C30 in patients diagnosed with breast cancer)</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">490</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>localized disease or locally advanced disease</arm_group_label>
    <description>Subgroups:
A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metastatic disease</arm_group_label>
    <description>Subgroups:
A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy F: No Surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>follow up disease</arm_group_label>
    <description>Subgroups:
A: BCT/Ablatio + /-SN Biopsie + /- Irradiation B: BCT/Ablatio + axill Diss C: Chemotherapy D: Antihormonal Therapy E: Target Therapy F: No Surgery</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study sample will be composed of a series of consecutive cancer patients who meet the
        study eligibility criteria in each participating centre
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed diagnosis of breast cancer

          -  no previous primary or recurrent tumour

          -  ability to understand the language of the questionnaire

          -  mental fitness to complete a questionnaire

          -  18 years of age or above

          -  written informed consent.

        Exclusion Criteria:

          -  no histologically confirmed diagnosis of breast cancer

          -  previous primary or recurrent tumour

          -  not mentally fit to complete a questionnaire

          -  not able to understand the language of the questionnaire

          -  younger than 18

          -  refusal of informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vesna Bjelic-Radisic</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Universitiätsklinikum Wuppertal, Universität Witten/Herdecke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vesna Bjelic-Radisic</last_name>
    <phone>+49 202 896-1411</phone>
    <email>Vesna.Bjelic-Radisic@helios-gesundheit.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sina Schafer</last_name>
    <phone>+49 202 896-1475</phone>
    <email>Sina-Maria.Schafer@helios-gesundheit.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helios Universitiätsklinikum Wuppertal, Universität Witten/Herdecke</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vesna Bjelic-Radisic</last_name>
      <phone>+49 202 896-1411</phone>
      <email>Vesna.Bjelic-Radisic@helios-gesundheit.de</email>
    </contact>
    <contact_backup>
      <last_name>Sina Schafer</last_name>
      <phone>+49 202 896-1475</phone>
      <email>Sina-Maria.Schafer@helios-gesundheit.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996 Oct;14(10):2756-68.</citation>
    <PMID>8874337</PMID>
  </reference>
  <reference>
    <citation>Bjelic-Radisic, V. (2018, October). An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23)- EORTC QLQ-BR45. Presentation at the European Society for Medical Oncology [ESMO] Congress, Munich, Germany.</citation>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

